Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 12 Diseases   14 Trials   14 Trials   524 News 


123456789»
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
    Journal, HEOR, Patient reported outcomes:  De-simplifying antiretroviral therapy from a single-tablet to a two-tablet regimen: Acceptance, patient-reported outcomes, and cost savings in a multicentre study. (Pubmed Central) -  Nov 14, 2024   
    Whether viral load testing for children with HIV is necessary to inform NRTI choice depends substantially on the comparative outcomes of abacavir and zidovudine after switching to dolutegravir-containing ART. De-simplification from an STR to a TTR within the Dutch healthcare setting has been demonstrated as feasible, leads to significant cost reductions and should be discussed with every eligible person with HIV in the Netherlands.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Endogenous retroviruses and the association with TDP-43 and neuroinflammation in amyotrophic lateral sclerosis (Poster Hall at the Palais de Congres Montreal; 517b/c) -  Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_452;    
    Antiretroviral therapy known as Triumeq is being trialled as in a phase III trial after promising phase IIa results (2)...Instead, this increased expression is proposed to be caused by an increase of neuro-inflammatory mediators of expression including TNF-?.These results suggest a link between an increased inflammatory response from exogenous viral infection and increased HERV expression that is independent of TDP-43, potentially involving inflammatory cytokines. The results from this study highlight the involvement of TDP-43 and neuroinflammation in HERV-K associated neurodegeneration in ALS pathology, and ongoing work will contribute towards the increasing the therapeutic benefit of antiretroviral therapy for ALS.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Incidence of comorbidities over 18 months with BIC/FTC/TAF, DTG/ABC/3TC or DTG/3TC in real?life settings in the ANRS?CO3?AquiVIH?NA cohort () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_214;    
    At month 18, we observed similar incidence rates of new diagnosis of diabetes, osteoporosis and cancer between the three strategies. We observed a trend for higher incidence of hypertension in the DTG/ABC/3TC group and of eGFR <60 ml/minute in the DTG groups than in the BIC/FTC/TAF group.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Long?acting cabotegravir/rilpivirine as a safe antiretroviral therapy in solid organ transplanted HIV patients () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_200;    
    Prior ARV were BIC/TAF/FTC (N = 3), and DTG/3TC and DTG/3TC/ABC one each...Concomitant immunosuppressants were: cyclosporin plus mycophenolate (N = 1), everolimus monotherapy (N = 1), everolimus plus prednisolone (N = 1), tacrolimus plus mycophenolate (N = 1); only the kidney recipient was on triple therapy with cyclosporin plus mycophenolate plus prednisone... LA with C/R may be considered in SOT patients as a safe and effective ARV.
  • ||||||||||  Antiretroviral therapy in pregnancy in England in 2019?2022: common regimens and treatment modifications () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_130;    
    Among pregnancies conceived on ART, most common (reported in >5%) first regimens were efavirenz (EFV) + tenofovir disoproxil fumarate (TDF) + emtricitabine (FTC) (13.5% [267/1974]), rilpivirine (RPV) +TDF+FTC (11.6% [228/1974]), darunavir/ritonavir (DRV/r) +TDF+FTC (8.0% [158/1974]), dolutegravir (DTG) + lamivudine (3TC) + abacavir (ABC) (7.7% [152/1974]), and raltegravir (RAL) +TDF+FTC (6.4% [127/1974]). Where ART was initiated during pregnancy (55.7% [234/420] diagnosed antenatally), median gestational age at start was 15 weeks (IQR 12
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Enrollment closed, Trial primary completion date:  LIGHTHOUSE II: Triumeq in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) -  Oct 8, 2024   
    P3,  N=390, Active, not recruiting, 
    The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Aug 2026
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Journal:  Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-na (Pubmed Central) -  Sep 27, 2024   
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Aug 2026 There is a high incidence of NAFLD in PLWH who start a second generation INSTI at 48
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Trial completion date, Trial primary completion date:  Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (clinicaltrials.gov) -  Sep 20, 2024   
    P3,  N=101, Active, not recruiting, 
    There is a high incidence of NAFLD in PLWH who start a second generation INSTI at 48 Trial completion date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jul 2024 --> Nov 2024
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Adempas (riociguat) / Bayer, Merck (MSD), Opsumit (macitentan) / Nippon Shinyaku, J&J
    THERAPEUTIC CHALLENGES OF HIV-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN THE CURRENT ANTIRETROVIRAL THERAPY ERA (Convention Center Exhibit Hall: Rapid Fire Area 4C) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_4522;    
    Clinicians must navigate a delicate balance between optimizing PAH treatment with riociguat and maintaining viral suppression with Triumeq, while minimizing the risk of adverse events and treatment failure. Understanding the nuances of DDI is crucial for tailoring individualized treatment regimens and optimizing outcomes for patients with HIV-associated PAH.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Trial completion, Trial completion date, Trial primary completion date, Head-to-Head:  AVERTAS-1: Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals (clinicaltrials.gov) -  May 29, 2024   
    P4,  N=81, Completed, 
    Understanding the nuances of DDI is crucial for tailoring individualized treatment regimens and optimizing outcomes for patients with HIV-associated PAH. Recruiting --> Completed | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Enrollment change, Trial termination, Adherence:  TAISTR: Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (clinicaltrials.gov) -  May 9, 2024   
    P4,  N=33, Terminated, 
    Recruiting --> Completed | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 N=50 --> 33 | Unknown status --> Terminated; Sponsor decision due to slow recruitment rates and no future recruitment foreseen
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Emerging dolutegravir resistance in children and adolescents living with HIV in Malawi (Poster board: 133) -  May 2, 2024 - Abstract #AIDS2024AIDS_1459;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Prenatal dolutegravir-based regimen use, and pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (Poster board: 128) -  May 2, 2024 - Abstract #AIDS2024AIDS_1455;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  abacavir / Generic mfg.
    Journal:  The anti-HIV drug abacavir stimulates ?-catenin activity in osteoblast lineage cells. (Pubmed Central) -  Apr 9, 2024   
    Bone mineral density (BMD) loss in people living with HIV occurs with the initiation of combined antiretroviral therapy (cART), particularly with tenofovir disoproxil fumarate (TDF) containing cART...Primary human osteoblasts and male C57BL/6 mice were treated with individual antiretrovirals (ARVs) or a combination of ABC/DTG/lamivudine (3TC)...ABC, alone and as part of ABC/DTG/3TC, increased osteoblastic ?-catenin activity as indicated by increased TOPFlash activity, hypo-phosphorylated (active) ?-catenin staining, and ?-catenin targeted gene expression...Overall, our findings demonstrate that ABC activates Wnt/?-catenin signaling, but whether this leads to increased bone formation requires further study. Assessing the impact of ARVs on bone is critical to informing ARV selection and/or discovery of regimens that do not negatively impact the skeleton.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
    Emerging Integrase Resistance in the Perinatal Virtual Clinic: The Need for Protease Inhibitors (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_1329;    
    A second suppressed on nevirapine/3TC/ABC for 11 years simplified to DTG/3TC/ABC but failed 4 years later with an R263RK (intermediate DTG-R)...INSTI resistance is emerging in CALWHIV, most commonly in highly treatment experienced individuals from L/MIC. This highlights the global need for access to DRV/r, TXF and novel classes, including formulations for children <35kg.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Inflammatory Profile of B/F/TAF, DTG/ABC/3TC, and DTG+F/TAF Over 5 Years and Effects of Viral Blips (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_831;    
    This highlights the global need for access to DRV/r, TXF and novel classes, including formulations for children <35kg. Viral suppression was associated with significantly reduced inflammation in treatment-na
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    A Single Once Daily ABC/DTG/3TC Tablet Predicts Safe and Effective Exposures in Children 3 to (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_764;    
    Predicted drug exposures support the potential use of a single FDC of ABC/DTG/3TC DT in infants weighing 3-<6kg (aged ?4 weeks), with efficacy and safety expected to be comparable to prior pediatric studies in children ?6kg. The once daily single tablet treatment option may be a practical solution for infants with early HIV diagnosis.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    IMMUNE COMPLEX-MEDIATED NEPHROPATHY AS AN INITIAL MANIFESTATION OF ACUTE HIV INFECTION: CASE REPORT (SAT-283; Exhibition Hall and Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1687;    
    Immune complex-mediated lesions typically occur after years of illness, usually in patients with good disease control. There are no reported cases in the literature of HIVICK as the initial renal manifestation of acute HIV infection.
  • ||||||||||  Antiretroviral Regimens Are Associated With Cognitive Function in People With HIV (Poster hall) -  Mar 5, 2024 - Abstract #CROI2024CROI_515;    
    Tenofovir (including TAF or TDF) and FTC were common in such regimens in combination with either DRV+COBI, RPV, or EFV. Our findings suggest complex associations between ART regimens and cognition, such that specific ART combinations rather than individual agents are associated with cognition.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (clinicaltrials.gov) -  Feb 15, 2024   
    P3,  N=101, Active, not recruiting, 
    Although rare, severe hyponatremia is a known complication of Paxlovid Recruiting --> Active, not recruiting | N=300 --> 101 | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Review, Journal:  Biktarvy for the treatment of HIV infection: Progress and prospects. (Pubmed Central) -  Nov 6, 2023   
    megan.dubowsky@flinders.edu.au Based on the accumulated evidence from HIV clinical trials and real-world studies, the clinical effectiveness of BIC
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Early virological failure with Cabotegravir plus Rilpivirine in clinical practice (ePosters) -  Oct 8, 2023 - Abstract #EACS2023EACS_1550;    
    In our case, probably the cause of VF was the pre-existence of NNRTI mutations together with low CAB concentrations. The availability of a baseline genotype, regardless of VF history or NNRTI exposure, may be key in making decisions to switch to CAB+RPV LA-2M.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
    Early virological failure with Cabotegravir plus Rilpivirine in clinical practice (ePosters) -  Oct 8, 2023 - Abstract #EACS2023EACS_1549;    
    In our case, probably the cause of VF was the pre-existence of NNRTI mutations together with low CAB concentrations. The availability of a baseline genotype, regardless of VF history or NNRTI exposure, may be key in making decisions to switch to CAB+RPV LA-2M.